Arcus_JPM-2025-Presentation_FINAL

COMBININGTO CURE®Arcus is at the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer.January 14, 2025CORPORATE PRESENTATION© Arcus Biosciences 2025Forward Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. (“we,” “Arcus” or the “Company”) made pursuant to thesafe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the futurecontained in this presentation are forward-looking statements, including statements about: our strategy, advantages, and expectations, including regarding our productivity and competitiveness; expectation that our cash and investments are sufficient to fund operations into mid-2027; potentialof our investigational products and portfolio, including our investigational products potential to be best or first in class; anticipated benefits of our collaborations